Reported Earnings • Apr 27
Full year 2025 earnings released: EPS: CN¥1.09 (vs CN¥1.12 in FY 2024) Full year 2025 results: EPS: CN¥1.09 (down from CN¥1.12 in FY 2024). Revenue: CN¥1.27b (up 5.3% from FY 2024). Net income: CN¥246.3m (down 2.8% from FY 2024). Profit margin: 19% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Apr 27
Shenzhen Weiguang Biological Products Co., Ltd., Annual General Meeting, May 18, 2026 Shenzhen Weiguang Biological Products Co., Ltd., Annual General Meeting, May 18, 2026, at 14:30 China Standard Time. Location: 4F, No. 3402, Guangqiao Avenue, Guangming Subdistrict, Guangming District, Shenzhen, Guangdong China Board Change • Apr 10
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Yanmei Wang was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Mar 31
Shenzhen Weiguang Biological Products Co., Ltd. to Report Q1, 2026 Results on Apr 27, 2026 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report Q1, 2026 results on Apr 27, 2026 Announcement • Dec 31
Shenzhen Weiguang Biological Products Co., Ltd. to Report Fiscal Year 2025 Results on Apr 27, 2026 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report fiscal year 2025 results on Apr 27, 2026 Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: CN¥0.22 (vs CN¥0.32 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.22 (down from CN¥0.32 in 3Q 2024). Revenue: CN¥272.8m (down 18% from 3Q 2024). Net income: CN¥50.2m (down 31% from 3Q 2024). Profit margin: 18% (down from 22% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Sep 30
Shenzhen Weiguang Biological Products Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Declared Dividend • Jul 14
Dividend of CN¥0.20 announced Shareholders will receive a dividend of CN¥0.20. Ex-date: 17th July 2025 Payment date: 17th July 2025 Dividend yield will be 0.7%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (18% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 76 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jul 02
Shenzhen Weiguang Biological Products Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025 New Risk • May 13
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Apr 25
Shenzhen Weiguang Biological Products Co., Ltd. Proposes Final Cash Dividend for the Year 2024 Shenzhen Weiguang Biological Products Co., Ltd. announced on 23 April 2025 the profit distribution proposal for 2024: Final Cash dividend (tax included) of CNY 2.00000000 per 10 shares. Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.19 (vs CN¥0.21 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.19 (down from CN¥0.21 in 1Q 2024). Revenue: CN¥225.0m (flat on 1Q 2024). Net income: CN¥43.8m (down 6.5% from 1Q 2024). Profit margin: 20% (down from 21% in 1Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Announcement • Apr 23
Shenzhen Weiguang Biological Products Co., Ltd., Annual General Meeting, May 19, 2025 Shenzhen Weiguang Biological Products Co., Ltd., Annual General Meeting, May 19, 2025, at 14:30 China Standard Time. Location: 3F, No. 3402, Guangqiao Avenue, Guangming Subdistrict, Guangming District, Shenzhen, Guangdong China Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥33.00, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 23x in the Biotechs industry in China. Total returns to shareholders of 15% over the past three years. Announcement • Mar 31
Shenzhen Weiguang Biological Products Co., Ltd. to Report Q1, 2025 Results on Apr 23, 2025 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025 Announcement • Dec 31
Shenzhen Weiguang Biological Products Co., Ltd. to Report Fiscal Year 2024 Results on Apr 23, 2025 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report fiscal year 2024 results on Apr 23, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.22 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.32 (up from CN¥0.22 in 3Q 2023). Revenue: CN¥331.2m (up 19% from 3Q 2023). Net income: CN¥72.8m (up 45% from 3Q 2023). Profit margin: 22% (up from 18% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Sep 30
Shenzhen Weiguang Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥28.66, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 22x in the Biotechs industry in China. Total returns to shareholders of 1.7% over the past three years. Announcement • Jun 29
Shenzhen Weiguang Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 New Risk • May 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥34.60, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 27x in the Biotechs industry in China. Total returns to shareholders of 8.0% over the past three years. Announcement • Apr 28
Shenzhen Weiguang Biological Products Co., Ltd., Annual General Meeting, May 17, 2024 Shenzhen Weiguang Biological Products Co., Ltd., Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: 4F, No. 3402, Guangqiao Avenue, Guangming Subdistrict, Guangming District, Shenzhen, Guangdong China Agenda: To consider . 2023 annual report and its summary; to consider 2023 work report of the board of directors; to consider 2023 work report of the supervisory committee; to consider 2023 profit distribution plan; to consider 2024 application for comprehensive credit line to banks; to consider Adjustment of the allowance for independent directors; to consider By-election of directors; and to consider other related matters. Announcement • Apr 27
Shenzhen Weiguang Biological Products Co., Ltd. Proposes Final Cash Dividend for the Year 2023 Shenzhen Weiguang Biological Products Co., Ltd. announced on 26 April 2024 the profit distribution proposal for 2023: Cash dividend (tax included) of CNY 2.00000000 per 10 shares. Buy Or Sell Opportunity • Apr 22
Now 22% overvalued Over the last 90 days, the stock has fallen 2.0% to CN¥28.61. The fair value is estimated to be CN¥23.50, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 7.0%. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to grow by 55% in the next 2 years. Announcement • Mar 30
Shenzhen Weiguang Biological Products Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Buy Or Sell Opportunity • Mar 29
Now 22% overvalued Over the last 90 days, the stock has fallen 19% to CN¥28.46. The fair value is estimated to be CN¥23.31, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 7.0%. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to grow by 55% in the next 2 years. Buy Or Sell Opportunity • Mar 08
Now 20% overvalued Over the last 90 days, the stock has fallen 27% to CN¥27.82. The fair value is estimated to be CN¥23.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 7.0%. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to grow by 55% in the next 2 years. Buy Or Sell Opportunity • Feb 20
Now 20% overvalued Over the last 90 days, the stock has fallen 22% to CN¥28.37. The fair value is estimated to be CN¥23.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 7.0%. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to grow by 55% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥24.49, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 23x in the Biotechs industry in China. Total loss to shareholders of 30% over the past three years. Announcement • Dec 29
Shenzhen Weiguang Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Announcement • Oct 25
Shenzhen Weiguang Biological Products Co., Ltd. Announces Interim Profit Distribution Plan to Be Implemdented (A Shares) for 2023, Payable on 31 October 2023 Shenzhen Weiguang Biological Products Co., Ltd. announced 2023 interim profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 2.00000000. Record date: 30 October 2023, Ex-date: 31 October 2023, Payment date: 31 October 2023. Announcement • Sep 30
Shenzhen Weiguang Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023 Announcement • Sep 19
Shenzhen Weiguang Biological Products Co., Ltd. Announces Interim Dividend for Year 2023 Shenzhen Weiguang Biological Products Co., Ltd. held its 3rd Extraordinary General Meeting of 2023 on 15 September 2023, announced interim Cash dividend/10 shares (tax included): CNY 2.00000000 for the year 2023. Announcement • Aug 26
Shenzhen Weiguang Biological Products Co., Ltd. Proposes Interim Cash Dividend for the First Half of 2023 Shenzhen Weiguang Biological Products Co., Ltd. proposed interim cash dividend per 10 shares (tax included) of CNY 2.00000000 for the first half of 2023. Announcement • Jul 01
Shenzhen Weiguang Biological Products Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Shenzhen Weiguang Biological Products Co., Ltd. announced that they will report first half, 2023 results on Aug 25, 2023 Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥40.32, the stock trades at a trailing P/E ratio of 66.3x. Average trailing P/E is 42x in the Biotechs industry in China. Total loss to shareholders of 5.6% over the past three years. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Jul 06
Shenzhen Weiguang Biological Products Co., Ltd. Announces Cash Dividend on A Shares for 2021, Payable on 8 July 2022 Shenzhen Weiguang Biological Products Co., Ltd. announced cash dividend of CNY 2.00000000 per 10 shares (tax included) (A shares) for 2021. Record date: 07 July 2022. Ex-date: 08 July 2022. Payment date: 08 July 2022. Announcement • May 15
Shenzhen Weiguang Biological Products Co., Ltd. Approves Cash Dividend for the Year 2021 Shenzhen Weiguang Biological Products Co., Ltd. announced that at the AGM was held on 12 May 2022, the company approved the cash dividend/10 shares (tax included): CNY 2.00000000 for the year 2021. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Mar 10
Shenzhen Weiguang Biological Products Co., Ltd. announced that it expects to receive CNY 1.15 billion in funding Shenzhen Weiguang Biological Products Co., Ltd. announced a private placement of not more than 34,340,000 shares for gross proceeds of not more than CNY 1,150,000,000 on March 9, 2022. The issue price is not less than 80% of the average price in the 20 trading days before the pricing reference date. The transaction will include participation from not more than 35 investors. All securities issued in the transaction have a hold period of 6 months. The transaction has been approved in the 2nd meeting of it’s 3rd directorate and by 65.25% shareholder Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, and is subject to the approvals of the it's shareholders and the China Securities Regulatory Commission. Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥36.01, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 36x in the Biotechs industry in China. Total returns to shareholders of 70% over the past three years. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.19 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥281.0m (up 40% from 3Q 2020). Net income: CN¥67.7m (up 56% from 3Q 2020). Profit margin: 24% (up from 22% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 14% per year. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.20 in 2Q 2020) The company reported a poor second quarter result with weaker earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: CN¥197.1m (down 9.6% from 2Q 2020). Net income: CN¥43.0m (down 6.2% from 2Q 2020). Profit margin: 22% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 22
Shenzhen Weiguang Biological Products Co., Ltd. Approves Cash Dividend for the Year 2020 Shenzhen Weiguang Biological Products Co.,Ltd announced at the AGM held on May 20, 2021 has approved a cash dividend (tax included) of CNY 2.50000000 per ten shares for the year 2020. Announcement • Mar 10
Shenzhen Weiguang Biological Products Co.,Ltd to Report Fiscal Year 2020 Results on Apr 23, 2021 Shenzhen Weiguang Biological Products Co.,Ltd announced that they will report fiscal year 2020 results on Apr 23, 2021 Is New 90 Day High Low • Dec 29
New 90-day low: CN¥47.27 The company is down 16% from its price of CN¥56.55 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 26
New 90-day low: CN¥47.87 The company is down 19% from its price of CN¥59.03 on 28 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 13% over the same period. Is New 90 Day High Low • Oct 22
New 90-day low: CN¥51.95 The company is down 13% from its price of CN¥59.45 on 24 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period. Announcement • Oct 20
Shenzhen Weiguang Biological Products Co.,Ltd to Report Q3, 2020 Results on Oct 28, 2020 Shenzhen Weiguang Biological Products Co.,Ltd announced that they will report Q3, 2020 results on Oct 28, 2020 Announcement • Jul 25
Shenzhen Weiguang Biological Products Co.,Ltd to Report First Half, 2020 Results on Aug 21, 2020 Shenzhen Weiguang Biological Products Co.,Ltd announced that they will report first half, 2020 results on Aug 21, 2020